A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
← catalyst calendarNCT07220772 · readout in 303 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
4estimated
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-09 | actual | When the study began enrolling |
| Primary completion | 2027-06-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-21 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Monogenic Obesity
Intervention
- Drug: Mibavademab — also filed as REGN4461
Primary outcome
what the primary-completion date above is the date OFPercent change in Body Mass Index (BMI)
measured Baseline to Week 24
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed